<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9307339</article-id><article-id pub-id-type="doi">10.1155/2022/4364779</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>MiR-199 Aggravates Doxorubicin-Induced Cardiotoxicity by Targeting TAF9b</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Yangsheng</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Degang</given-names></name><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3090-445X</contrib-id><name><surname>Zhao</surname><given-names>Lin</given-names></name><email>zhaolin55609@163.com</email><xref rid="I3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Cardiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China</aff><aff id="I2">
<sup>2</sup>Emergency Department, Third People's Hospital of Liaocheng City, Liaocheng 252000, China</aff><aff id="I3">
<sup>3</sup>Department of Cardiology, Sunshine Union Hospital of Weifang, Weifang 261000, Shandong, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Zhaoqi Dong</p></fn></author-notes><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>15</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>7</month><year>2022</year></pub-date><volume>2022</volume><elocation-id>4364779</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2022</year></date><date date-type="rev-recd"><day>4</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2022</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2022 Yangsheng Yu et al.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The clinical application of doxorubicin (DOX) is limited because of its cardiotoxicity. However, the pathogenic mechanism of DOX and the role of miRNA in DOX-induced cardiotoxicity remain to be further studied. This study aimed to investigate the role of miR-199 in DOX-mediated cardiotoxicity. A mouse model of myocardial cell injury induced by DOX was established. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression changes of miR-199 and TATA-binding protein associated factor 9B (TAF9b) in DOX-induced cardiac injury. Cell apoptosis was detected by TUNEL staining and flow cytometry. The expression levels of apoptosis-related proteins, namely, Bax and Bcl-2, were detected by qPCR. The expression of Beclin-1 and LC3b was detected by western blotting. The binding effect of miR-199 with TAF9b was verified by dual-luciferase reporter gene assay. In this study, overexpression of miR-199 could promote cardiotoxicity. Inhibition of miR-199 could alleviate DOX-mediated myocardial injury. Further studies showed that miR-199 targeted TAF9b. Moreover, miR-199 promoted apoptosis of myocardial cells and aggravated autophagy. Furthermore, we demonstrated that TAF9B knockdown reversed the myocardial protective effect of miR-199 inhibitors. Therefore, miR-199 promoted DOX-mediated cardiotoxicity by targeting TAF9b, thereby aggravating apoptosis and regulating autophagy.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Doxorubicin (DOX) is an effective and commonly implemented anticancer drug for hematological diseases and solid tumors, and it is implemented as a first-line drug for a variety of cancers [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. However, DOX can lead to multiple-organ toxicity in patients. As an anticancer agent, DOX can lead to long-term dose-dependent cardiotoxicity and heart failure [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. Mechanisms of DOX-mediated myocardial injury comprised cardiomyocyte abiosis [<xref rid="B6" ref-type="bibr">6</xref>], atrophy [<xref rid="B7" ref-type="bibr">7</xref>], autophagy disturbance [<xref rid="B8" ref-type="bibr">8</xref>], and oxidative stress [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>The molecular mechanisms of DOX-induced cardiotoxicity have been extensively reported [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>]. At present, free radicals produced by DOX are the primary cause of cardiotoxicity, involving nonenzymatic pathways mediated by Fe<sup>3+</sup> and enzymatic pathways involved in antioxidant-related enzymes [<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>]. Thus, antioxidants prevent or mitigate cardiotoxicity induced by the elimination of excess free radicals produced by DOX.</p><p>MiRNAs are small noncoding RNAs that regulate the stability or translation of messenger RNA by interacting with specific sequences in the coding or untranslated regions to control gene expression. In recent years, its role in cardiovascular diseases has been slowly discovered, such as atherosclerosis [<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>], myocardial infarction [<xref rid="B20" ref-type="bibr">20</xref>], ischemia-reperfusion injury [<xref rid="B21" ref-type="bibr">21</xref>], and diabetic cardiomyopathy [<xref rid="B22" ref-type="bibr">22</xref>]. The mechanism of myocardial protection includes anti-apoptosis [<xref rid="B23" ref-type="bibr">23</xref>], inhibition of inflammation [<xref rid="B21" ref-type="bibr">21</xref>], and improvement of fibrosis to delay myocardial remodeling [<xref rid="B22" ref-type="bibr">22</xref>]. The role of miR-199 in DOX-mediated cardiomyopathy is included, particularly its effect on acute myocardial injury. Myocardial injury occurs in most patients after long-term administration of DOX [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>], but the role of miR-199 in cardiotoxicity mediated by DOX remains unknown.</p><p>TAF9b is a factor related to TATA-binding protein (TBP) [<xref rid="B26" ref-type="bibr">26</xref>]. TAF9b can bind to tumor suppressor proteins (p53). TAF9b participates in apoptosis by regulating p53 proteins [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>]. In previous studies, some scholars have proposed that TAF9b plays an indispensable role in transcriptional regulation [<xref rid="B29" ref-type="bibr">29</xref>]. Herein, we demonstrate that miR-199 aggravates apoptosis and regulates autophagy during DOX-mediated chronic cardiotoxicity by targeting TAF9b. It may be a new therapeutic target for cardiotoxicity mediated by oxidoreductase.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Animal Experiments</title><p>All the experiments were approved by the Animal Experimental Ethics Committee of Sunshine Union Hospital of Weifang. Eight-week-old female C57BL/6 mice were obtained from the Shanghai Model Organisms Center (Shanghai, China). C57BL/6 mice were raised in sterile filtration top cages with controlled humidity, a 12-hour day-night cycle, and a temperature of 22&#x000b0;C. Standard rodent food and tap water were provided randomly. Mice were intraperitoneally injected with Adriamycin (5&#x02009;mg/kg; Sigma-Aldrich, St. Louis, USA, MO) weekly for 4 weeks, and then placed for 2 weeks to ensure complete absorption and effectiveness [<xref rid="B30" ref-type="bibr">30</xref>]. The mice were anesthetized with pentobarbital sodium (43&#x02009;mg/kg iv) [<xref rid="B31" ref-type="bibr">31</xref>]. Blood and heart samples were collected at different time points to measure the changes of miR-199 under DOX stimulation. After the experiment, the mice were euthanized with CO<sub>2</sub> and were put in a clean container. CO<sub>2</sub> was injected at a rate of 20% per minute to replace the volume of the euthanasia box. After 10 minutes, make sure the mice are not moving, not breathing, and the pupils are dilated. Turn off CO<sub>2</sub> and observe for another 2 minutes. The mice were confirmed to be completely dead.</p></sec><sec id="sec2.2"><title>2.2. HE Staining</title><p>Heart tissue was removed from a neutral formalin solution. After 24&#x02009;h of running water washing, gradient alcohol dehydration was performed. Then, the tissue was dewaxed using xylene. After paraffin embedding, sectioning, xylene dewaxing, and staining for 15&#x02009;min, sappan wood semen was washed with running water. After 30&#x02009;s of blue infusion, the sample was rinsed with water for 15&#x02009;min. Afterward, eosin staining and alcohol dehydration were performed. Finally, xylene and neutral resin sealing was conducted. The images were observed and collected under a light microscope (Nikon, Japan).</p></sec><sec id="sec2.3"><title>2.3. Cell Lines and Culture Conditions</title><p>The AC16 cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in a wet incubator containing 95% air and 5% CO<sub>2</sub> at 37&#x000b0;C. The culture medium was Dulbecco's modified Eagle's medium (HyClone, USA)&#x02009;+&#x02009;10% fetal bovine serum (Gibco, Life Technologies, Rockville, MA, USA). The culture medium was refreshed every 3 days, and when the cell density reached about 80%, the culture medium was replaced with serum-free DMEM for 12&#x02009;h. Then, DOX (0.5&#x02009;<italic>&#x003bc;</italic>M) [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>] was implemented to induce cardiomyocyte injury.</p></sec><sec id="sec2.4"><title>2.4. Cell Transfection</title><p>MiR-199 mimics and inhibitors (Ribobio, China) were implemented to overexpress and downregulate miR-199 in vitro. We synthesized a small interfering RNA to knock out TAF9b (GenePharma, China). Random sequence molecules were synthesized as negative control. Control overexpression plasmids (100&#x02009;nM), TAF9b overexpression plasmids (100&#x02009;nM), were constructed by Shanghai GenePharma Co., Ltd. AC16 cells were inoculated in a well plate containing antibiotic-free medium at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/ml and cultured overnight. Lipofectamine&#x02122;3000 (Life Technologies, Rockville, MA, USA) was transfected into OPTI-MEM-reduced serum medium (Gibco, USA) for 48&#x02009;h according to production instructions. The influence of intervention was evaluated by real-time polymerase chain reaction (PCR).</p></sec><sec id="sec2.5"><title>2.5. Preparation and Analysis of RNA</title><p>Total RNA was extracted from cells and myocardial tissues with Trizol reagent (Invitrogen, USA) and reverse transcribed into cDNA with PrimeScript RT kit (Japanese Plateau City). Then, TB Green Premix Ex Taq II (Takara, Japan) was used to quantitatively amplify cDNA. Real-time PCR was performed in triplicate using the 6Flex application biology system. The expression of TAF9b was related to the expression of GAPDH gene. The expression of relative miR-199 was normalized to the expression of RNA (SnRNA) in U6. The amplification reaction conditions were pre-denaturation at 94&#x000b0;C for 2&#x02009;min, denaturation at 94&#x000b0;C for 30&#x02009;s, annealing at 49.3&#x000b0;C for 30&#x02009;s, and extension at 72&#x000b0;C for 2&#x02009;min, a total of 33 cycles. Finally, it was extended at 72&#x000b0;C for 5&#x02009;min The primer sequence was as follows: MiR-199, F: 5&#x02032;-AGAAGGCGATTGATACGAGTCA-3&#x02032;, R: 5&#x02032;-GGTCTCCCCAGTGTTCAGATA-3&#x02032;. TAF9b, F: 5&#x02032;-CGCAAGAGAAAATGGAGCCG-3&#x02032;, R: 5&#x02032;-CATCGTCCAGAATTGTAGTCACA-3&#x02032;. Bcl-2, F: 5&#x02032;-ATGCCTTTGTGGAACTATATGGC-3&#x02032;, R: 5&#x02032;-GGTATGCACCCAGAGTGATGC; Bax, F: 5&#x02032;-TGAAGACAGGGGCCTTTTTG-3&#x02032;, R: 5&#x02032;-AATTCGCCGGAGACACTCG-3&#x02032;; U6, F: 5&#x02032;-GCTTCGGCAGCACATATACTAAAAT-3&#x02032;, R: 5&#x02032;-CGCTTCAGAATTTGCGTGTCAT-3&#x02032;; GAPDH, F: 5&#x02032;-CGCTCTCTGCTCCTCCTGTTC-3&#x02032;, R: 5&#x02032;-ATCCGTTGACTCCGACCTTCAC-3&#x02032;. The PCR product was analyzed by ABI PRISM 7300 sequence detection systems (Applied Biosystems, Foster City, CA, USA). The expression of the target gene was calculated by 2<sup>&#x02212;&#x025b3;&#x025b3;CT</sup> method.</p></sec><sec id="sec2.6"><title>2.6. Dual-Luciferase Reporter Assay</title><p>The fragment of TAF9b mRNA containing miR-195 binding sites was inserted into the psiCHECK-2 luciferase reporter vector (Promega, Madison, WI, USA). The mutant plasmids were known as TAF9b-Mut. The abovementioned plasmid was transfected into cells containing NC mimics or miR-199 mimics by Lipofectamine 2000.48&#x02009;h after transfection, the luciferase activities were measured using the dual-luciferase reporter assay system (Promega). Follow the instructions of the technical manual for the dual-luciferase reporter gene test kit. The internal reference of psiCHECK2 vector was firefly luciferase activity. The expression of psicheck2-TAF9B-3 UTR WT and psicheck2-TAF9B-3 UTRMUT were controls. Fluorescence intensity was detected 24&#x02009;h after transfection. The ratio of the luminescence intensity of sea cucumber luciferase to that of firefly luciferase is the binding force of miR-199 and TAF9b.</p></sec><sec id="sec2.7"><title>2.7. ELISA Assay</title><p>The activity of superoxide dismutase 1 (SOD), malondialdehyde (MDA), lactate dehydrogenase (LDH), tumor necrosis factor-<italic>&#x003b1;</italic> (TNF-<italic>&#x003b1;</italic>), interleukin-1<italic>&#x003b2;</italic> (IL-1<italic>&#x003b2;</italic> cells), and interleukin-6 (IL-6) was measured using commercial kits from Nanjing Jiancheng Institute of Biological Engineering.</p></sec><sec id="sec2.8"><title>2.8. Flow Cytometry</title><p>To detect the apoptotic rate, the cells were seeded in 12-well plates at the seeding density of 3&#x02009;&#x000d7;&#x02009;10<sup>5</sup>/well and cultured for 48&#x02009;h. Thereafter, the cells were washed twice with PBS, resuspended in binding buffer, and then added with Annexin V-FITC and propidium iodide (PI) in the dark for 15&#x02009;min at 37&#x000b0;C. The cell apoptosis rate was analyzed by flow cytometry within 1&#x02009;h.</p></sec><sec id="sec2.9"><title>2.9. TUNEL Staining</title><p>TUNEL apoptosis detection kit (Alexa Fluor488; Yeasen, China) was used to detect nuclear fragmentation according to the regulations of the manufacturer. For TUNEL staining of AC16&#x02009;s, the cells were washed with PBS and fixed with 4% paraformaldehyde. Tissue sections and cells were incubated with protease K for 5&#x02009;min, permeability solution 0.1% and Triton X-100 in 4&#x000b0;C for 2&#x02009;min. Rinse cells with PBS twice, 5&#x02009;min each. TUNEL reaction solution (TdT&#x02009;+&#x02009;fluorescein labeled dUTP) was added, and incubated in a wet box at 37&#x000b0;C for 60&#x02009;min in the dark. Wash cells with PBS for 3 times, 5&#x02009;min each, and stained with Hoechst33342 (Beyotime Biotechnology, China). In fluorescent staining, the nuclei appear to be morphologically altered by blue fluorescence. Then, the apoptotic cells were observed under a fluorescence microscope (Nikon, Japan) and counted from five randomly selected regions by image J.</p></sec><sec id="sec2.10"><title>2.10. Western Blot</title><p>AC16 cells were collected after DOX treatment for 24&#x02009;h. After the cells were treated with cell lysate, an appropriate amount of electrophoresis sample buffer was added. Afterward, the sample was heated in boiling water for 10&#x02009;min, and then electrophoresis in 12% polyacrylamide gel was performed. The sample was blocked with 3% BSA for 2&#x02009;h [<xref rid="B25" ref-type="bibr">25</xref>] at 37&#x000b0;C. Mouse anti-human Beclin-1 (Abcam, 1&#x02009;:&#x02009;1000, Cambridge, MA, USA), LC3B (Abcam, 1&#x02009;:&#x02009;1000) antibody, and mouse anti-human GAPDH (Abcam, 1&#x02009;:&#x02009;1000) were added overnight at 4&#x000b0;C and washed with PBST three times each time. The corresponding secondary antibody labeled with HRP was added, incubated at 37&#x000b0;C for 30&#x02009;min, and washed with PBST three times for 15&#x02009;min each time. The results were visualized by Odyssey Infrared Imaging System.</p></sec><sec id="sec2.11"><title>2.11. Statistical Analysis</title><p>All data were expressed as mean&#x02009;&#x000b1;&#x02009;SD of at least three independent experiments. SPSS 22.0 software (SPSS Inc., Chicago, IL, USA) was implemented for statistical analysis. The difference between the two groups was tested by Student's <italic>t</italic>-test. Bonferroni posttest was performed following one-way ANOVA and was considered statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. DOX-Induced Myocardial Cell Injury (AC16 Cells)</title><p>We used Adriamycin (0.5&#x02009;<italic>&#x003bc;</italic>m) to establish the myocardial cell injury model in vitro, and study the effects of Adriamycin on AC16 cells. The experimental results showed that the cell proliferation rate in the DOX-induced group was significantly lower than that in the control group (<xref rid="fig1" ref-type="fig">Figure 1(a)</xref>). We also detected the inflammatory factors in the two groups. The results revealed that TNF-<italic>&#x003b1;</italic>, IL-1<italic>&#x003b2;</italic>, and IL-6 in the DOX-induced group were evidently high (<xref rid="fig1" ref-type="fig">Figure 1(b)</xref>). Then, we detected LDH, SOD, and MDA in the two groups. The results revealed that the LDH and MDA in the DOX-induced group were high with low MDA (<xref rid="fig1" ref-type="fig">Figure 1(c)</xref>). We used flow cytometry to detect apoptosis in the two groups. The results showed that the apoptotic rate in the DOX-mediated group was evidently high (<xref rid="fig1" ref-type="fig">Figure 1(d)</xref>). We performed TUNEL staining, and the results revealed that the apoptotic rate and Bax of the DOX-mediated group were high (<xref rid="fig1" ref-type="fig">Figure 1(e)</xref>). On the contrary, Bcl-2 of the DOX-mediated group was low (<xref rid="fig1" ref-type="fig">Figure 1(f)</xref>). Finally, Beclin-1 and LC3B-II in the DOX-induced group were higher than those in the matched group (<xref rid="fig1" ref-type="fig">Figure 1(h)</xref>). Therefore, DOX could damage AC16 cells.</p></sec><sec id="sec3.2"><title>3.2. DOX Promotes miR-199 Expression</title><p>Our study unmasked that DOX could promote the expression of miR-199. miR-199 of cardiomyocytes in the control and DOX-induced groups was quantified. The results revealed that miR-199 of cardiomyocytes in the DOX-induced group was high (<xref rid="fig2" ref-type="fig">Figure 2(a)</xref>). In addition, miR-199 of cardiomyocytes in the DOX-mediated group (5&#x02009;mg/kg) was higher than that in the matched group (<xref rid="fig2" ref-type="fig">Figure 2(b)</xref>). We further performed HE staining of DOX-induced myocardial injury in mice (<xref rid="fig2" ref-type="fig">Figure 2(c)</xref>). The results showed that the DOX-induced group had significantly increased myocardial cell damage compared with the control group. Therefore, DOX could promote miR-199 expression.</p></sec><sec id="sec3.3"><title>3.3. Overexpression of miR-199 Promotes Cardiotoxicity of DOX</title><p>Our study showed that overexpression of miR-199 could promote cardiotoxicity of DOX. First, miR-199 was divided into four groups induced with DOX. Each group of mimics-NC, miR-199 mimics, inhibitor-NC, and miR-199 inhibitor was prepared (<xref rid="fig3" ref-type="fig">Figure 3(a)</xref>). The results revealed that TNF-<italic>&#x003b1;</italic>, IL-1<italic>&#x003b2;</italic>, and IL-6 were overexpressed in the miR-199 mimic-transfected group (<xref rid="fig3" ref-type="fig">Figure 3(b)</xref>). Second, LDH, SOD, and MDA were detected, and we found that LDH and MDA were overexpressed in the miR-199 mimic group after transfection (<xref rid="fig3" ref-type="fig">Figure 3(c)</xref>). However, the expression of SOD in the miR-199 mimic group was low (<xref rid="fig3" ref-type="fig">Figure 3(c)</xref>). We used flow cytometry to detect apoptosis in each group and obtained the same results; the apoptotic rate of cells transfected with miR-199 mimics was the highest (<xref rid="fig3" ref-type="fig">Figure 3(d)</xref>). Then, we performed TUNEL staining to detect apoptosis in each group, and the results suggested that the apoptotic rate of cells transfected with miR-199 mimics was the highest (<xref rid="fig3" ref-type="fig">Figure 3(e)</xref>). The TUNEL staining results were consistent with the results of flow cytometry. We detected the expression of Bax and Bcl-2 in each group. The results displayed that Bax was overexpressed in the miR-199 mimic group after transfection (<xref rid="fig3" ref-type="fig">Figure 3(f)</xref>), and Bcl-2 expression was distinctly low in the miR-199 mimic group after transfection (<xref rid="fig3" ref-type="fig">Figure 3(g)</xref>). Finally, we concluded that the miR-199 mimic-transfected group was overexpressed (<xref rid="fig3" ref-type="fig">Figure 3(h)</xref>). Furthermore, the overexpression of miR-199 could promote the cardiotoxicity of DOX.</p></sec><sec id="sec3.4"><title>3.4. TAF9b Is a Target Gene Mediating the Regulatory Characteristics of miR-199</title><p>In our study, TAF9b is the target gene that mediates the regulatory characteristics of miR-199. The schematic diagram of the combination of miR-199 and TAF9b is shown in <xref rid="fig4" ref-type="fig">Figure 4(a)</xref>. Luciferase reporter assay revealed that the fluorescence activity of the TAF9b-WT group reduced markedly, whereas no difference was found in the TAF9b-MUT group. This result indicated that TAF9b was the target of miR-199a. Subsequently, we detected TAF9b expression of cardiomyocytes in the control and DOX-mediated groups (0.5&#x02009;<italic>&#x003bc;</italic>M) at the cellular level. The results displayed that TAF9b expression of cardiomyocytes in the DOX-mediated group (0.5&#x02009;<italic>&#x003bc;</italic>M) was lower than that of the matched group (<xref rid="fig4" ref-type="fig">Figure 4(c)</xref>). In addition, we detected TAF9b expression of cardiomyocytes in the control and DOX-induced groups (0.5&#x02009;<italic>&#x003bc;</italic>M) at the animal level. The results revealed that TAF9b of cardiomyocytes in the DOX-induced group was low (<xref rid="fig4" ref-type="fig">Figure 4(d)</xref>). We also found that the knockdown of miR-199 could upregulate the expression of TAF9b at the cellular level (<xref rid="fig4" ref-type="fig">Figure 4(e)</xref>). Therefore, we concluded that TAF9b was the target gene that mediated the regulatory characteristics of miR-199.</p></sec><sec id="sec3.5"><title>3.5. Knockdown of TAF9b Reverses the Cardioprotective Effect of miR-199 Inhibitor</title><p>Our study showed that the knockout of TAF9b could reverse the protective effect of miR-199 inhibitor on the myocardium. The induction of DOX was divided into the following groups: inhibitor-NC group, miR-199 inhibitor group, si-NC group, and miR-199 inhibitor&#x02009;+&#x02009;si-TAF9b group. First, the expression of TAF9b was detected in each group. The results indicated that the expression of TAF9b was high in the miR-199 inhibitor group (Figures <xref rid="fig5" ref-type="fig">5(a)</xref> and <xref rid="fig5" ref-type="fig">5(b)</xref>). Second, cell activity was detected, and the results revealed that the level of cell activity was the highest in the miR-199 inhibitor group (<xref rid="fig5" ref-type="fig">Figure 5(c)</xref>). Third, inflammatory cytokines were decreased in the miR-199 inhibitor group (<xref rid="fig5" ref-type="fig">Figure 5(d)</xref>). Fourth, LDH, SOD, and MDA of each group were detected, and the results revealed that LDH, SOD, and MDA in the miR-199 inhibitor group decreased evidently (<xref rid="fig5" ref-type="fig">Figure 5(e)</xref>). Fifth, the expression of Bax and Bcl-2 in each group was detected. The results revealed that Bax in the miR-199 inhibitor group was decreased (<xref rid="fig5" ref-type="fig">Figure 5(f)</xref>), whereas Bcl-2 in the miR-199 inhibitor group was evidently increased (<xref rid="fig5" ref-type="fig">Figure 5(f)</xref>). Therefore, the knockout of TAF9b could reverse the protective effect of miR-199 inhibitor on the myocardium.</p></sec><sec id="sec3.6"><title>3.6. Overexpression of TAF9b Reverses Injury Mediated by miR-199</title><p>Our study showed that overexpression of TAF9b could reverse the myocardial injury of miR-199. DOX induction was divided into the following groups: mimics-NC group, miR-199 mimic group, vector-NC group, and miR-199 mimics&#x02009;+&#x02009;TAF9b group. First, we detected the apoptosis in each group by flow cytometry. The results suggested that the apoptotic rate in the miR-199 mimic&#x02009;+&#x02009;TAF9b group was lower than that in the miR-199 mimic group (Figures <xref rid="fig6" ref-type="fig">6(a)</xref>-<xref rid="fig6" ref-type="fig">6(b)</xref>). Second, we used TUNEL staining to detect apoptosis in each group. The results revealed that the apoptotic rate in the miR-199 mimics&#x02009;+&#x02009;TAF9b group was evidently lower than that in the miR-199 mimic group (<xref rid="fig6" ref-type="fig">Figure 6(c)</xref>). Third, we detected the expression of Bax and Bcl-2 in each group. The results revealed that Bax in the miR-199 mimics&#x02009;+&#x02009;TAF9b group was evidently lower than that in the miR-199 mimic group (<xref rid="fig6" ref-type="fig">Figure 6(d)</xref>), and Bcl-2 in the miR-199 mimics&#x02009;+&#x02009;TAF9b group was distinctly lower than that in the miR-199 mimic group (<xref rid="fig6" ref-type="fig">Figure 6(e)</xref>). Finally, we detected autophagy-related proteins, including Beclin-1 and LC3B by western blot. The results showed that overexpression of miR-199 promoted the expression of Beclin-1 and LC3B compared with the control group. However, Beclin-1 and LC3B decreased in miR-199 mimics&#x02009;+&#x02009;TAF9b group (<xref rid="fig6" ref-type="fig">Figure 6(f)</xref>). Therefore, overexpression of TAF9b can reverse miR-199-mediated autophagy in cardiomyocytes.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>DOX is a widely used anticancer drug [<xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B37" ref-type="bibr">37</xref>]. However, the clinical application of DOX is limited because of its potential to cause severe heart failure and degenerative cardiomyopathy in the elderly patients with previous heart disease [<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>]. Its cardiotoxicity limits its clinical treatment. Although several mechanisms of toxicity have been proposed [<xref rid="B40" ref-type="bibr">40</xref>&#x02013;<xref rid="B42" ref-type="bibr">42</xref>], the mechanism of toxicity in other organs remains elusive, but the role of oxidative stress shows great potential as a mechanism of DOX-induced cardiotoxicity [<xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>]. Some scholars have proposed the adverse outcome pathway (AOP) mechanism, but AOP is still in its infancy, which plays a little role in the establishment of complex toxicology. However, the tools of AOP can be used for toxicology and risk assessment in the future, as it can comply with the OECD guidelines [<xref rid="B46" ref-type="bibr">46</xref>]. Chemically mediated skin allergy, cholestasis, and liver-related diseases are examples of AOPs [<xref rid="B47" ref-type="bibr">47</xref>]. In addition, in 6 to 8-week-old C57BL/6N mice, the destruction of intestinal epithelial cells was the common cause of adverse reactions caused by DOX (20&#x02009;mg/kg, i.p.), which led to the leakage of intestinal microorganism-related endotoxin and enhanced TLR4 signal. Immunotoxicity is caused by systemic inflammation and multiple-organ injury [<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>].</p><p>DOX can distinctly inhibit cell viability and cell respiration, induce cell morphological changes, and increase reactive oxygen species. Despite considerable evidence supporting the role of microRNAs (miRNAs) in dose-mediated myocardial injury, the definite pathogenesis remains unclear. miRNA-128-3p promotes oxidative stress by targeting Sirt1, which aggravates the damage mediated by oxidative stress to Dox [<xref rid="B50" ref-type="bibr">50</xref>]. Zhao et al. screened 18 differentially expressed microRNAs using the microRNA microarray analysis technique in rat heart tissue mediated by DOX [<xref rid="B51" ref-type="bibr">51</xref>]. The results displayed that DOX increased miR-140-5p. Liu et al. proposed that let-7f-2-3p regulated by lncRNA NEAT1 aggravated DOX-mediated cardiotoxicity by inhibiting the HAX-1 nuclear outlet [<xref rid="B52" ref-type="bibr">52</xref>]. Hanouskova et al. [<xref rid="B53" ref-type="bibr">53</xref>] reported that after DOX treatment, miR-34a and miR-130a expression evidently increased [<xref rid="B54" ref-type="bibr">54</xref>], whereas miR-502 expression decreased [<xref rid="B55" ref-type="bibr">55</xref>]. However, no change was found in miRNA expression associated with troponin T. A study on the changes of plasma miRNA expression in children mediated by DOX associated with markers of heart injury showed that plasma miR-499 and miR-29b enhanced after DOX induction [<xref rid="B56" ref-type="bibr">56</xref>]. MiR-15&#x02009;b-5p might be involved in DOX-mediated cardiotoxicity by suppressing the Bmpr1a signaling pathway in cardiomyocytes [<xref rid="B57" ref-type="bibr">57</xref>].</p><p>Autophagy is also an adaptive response, but when the external stimulation is excessive, the uncontrolled autophagy may not maintain the homeostasis of cardiomyocytes [<xref rid="B58" ref-type="bibr">58</xref>]. The complex interaction between cardiomyocyte apoptosis and autophagy determines the degree of myocardial damage and apoptosis [<xref rid="B59" ref-type="bibr">59</xref>]. In this study, the role of apoptosis and autophagy in DOX-mediated myocardial injury was investigated through low-dose long-term DOX intervention.</p><p>In previous studies, the role of autophagy in DOX-mediated myocardial injury has been widely debated [<xref rid="B60" ref-type="bibr">60</xref>&#x02013;<xref rid="B63" ref-type="bibr">63</xref>]. In our study, we found that the relative cell proliferation rate in the DOX induction group was evidently lower than that in the matched group; the inflammatory factors in the DOX induction group were higher; the LDH and MDA in the DOX induction group were evidently higher. In addition, we implemented TUNEL staining and found that the apoptotic rate in the DOX-induced group was higher than that of the matched group. Using flow cytometry, we found that the apoptotic rate and Bax in the DOX-mediated group were high, and Bcl-2 in the DOX-mediated group was lower than that in the matched group. Therefore, DOX could damage AC16 cells. We further discovered that DOX could promote the expression of miR-199, and overexpression of miR-199 could promote the cardiotoxicity of DOX. The expression of TAF9b in cardiomyocytes mediated by DOX (0.5&#x02009;<italic>&#x003bc;</italic>M) was low. However, at the cellular level, knockdown of miR-199 could upregulate the expression of TAF9b; therefore, TAF9b mediated the regulatory characteristics of miR-199. If the knockout of TAF9b could reverse the protective effect of miR-199 inhibitor on the myocardium, then the overexpression of TAF9b could reverse the effect of myocardial injury on miR-199. Li et al. found that miR-199 was associated with physiological myocardial hypertrophy in mice [<xref rid="B64" ref-type="bibr">64</xref>]. Moreover, Baumgarten et al. found that Twist1 modulated the activity of the ubiquitin-proteasome system in human end-stage dilated cardiomyopathy via miR-199 [<xref rid="B65" ref-type="bibr">65</xref>].</p><p>In this study, miR-199 could aggravate DOX-induced myocardial injury by targeting TAF9b through in vivo and in vitro experiments. This study is the first to report the relationship between miR-199 and TAF9b. It enriches the understanding of miRNA-mRNA regulatory interactions. However, further studies are needed before the clinical application of miR-199. In addition, the downstream regulatory mechanisms of TAF9B have not been fully elucidated.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>In this study, we found that miR-199 aggravates apoptosis and regulates autophagy in DOX-mediated cardiotoxicity by targeting TAF9b, and miR-199 may be a potential target for the treatment of DOX-mediated cardiotoxicity.</p></sec></body><back><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are available from the corresponding author upon request.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cardinale</surname><given-names>D.</given-names></name>
<name><surname>Colombo</surname><given-names>A.</given-names></name>
<name><surname>Bacchiani</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy</article-title><source>
<italic>Circulation</italic>
</source><year>2015</year><volume>131</volume><issue>22</issue><pub-id pub-id-type="doi">10.1161/circulationaha.114.013777</pub-id><pub-id pub-id-type="other">2-s2.0-84935443652</pub-id></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schilt</surname><given-names>Y.</given-names></name>
<name><surname>Berman</surname><given-names>T.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Barenholz</surname><given-names>Y.</given-names></name>
<name><surname>Raviv</surname><given-names>U.</given-names></name>
</person-group><article-title>Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs</article-title><source>
<italic>Biochimica et Biophysica Acta (BBA)&#x02014;General Subjects</italic>
</source><year>2016</year><volume>1860</volume><pub-id pub-id-type="doi">10.1016/j.bbagen.2015.09.012</pub-id><pub-id pub-id-type="other">2-s2.0-84946222927</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chou</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>J. M.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
</person-group><article-title>A tale of the two PEGylated liposomal doxorubicins</article-title><source>
<italic>OncoTargets and Therapy</italic>
</source><year>2015</year><volume>8</volume><pub-id pub-id-type="doi">10.2147/ott.s79089</pub-id><pub-id pub-id-type="other">2-s2.0-84937701782</pub-id></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>QuanJun</surname><given-names>Y.</given-names></name>
<name><surname>GenJin</surname><given-names>Y.</given-names></name>
<name><surname>LiLi</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Protective effects of dexrazoxane against doxorubicin-induced cardiotoxicity: a metabolomic study</article-title><source>
<italic>PLoS One</italic>
</source><year>2017</year><volume>12</volume><issue>1</issue><pub-id pub-id-type="publisher-id">e0169567</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0169567</pub-id><pub-id pub-id-type="other">2-s2.0-85009088577</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marchal</surname><given-names>S.</given-names></name>
<name><surname>Hor</surname><given-names>A. E.</given-names></name>
<name><surname>Millard</surname><given-names>M.</given-names></name>
<name><surname>Gillon</surname><given-names>V.</given-names></name>
<name><surname>Bezdetnaya</surname><given-names>L.</given-names></name>
</person-group><article-title>Anticancer drug delivery: an update on clinically applied nanotherapeutics</article-title><source>
<italic>Drugs</italic>
</source><year>2015</year><volume>75</volume><issue>14</issue><pub-id pub-id-type="doi">10.1007/s40265-015-0453-3</pub-id><pub-id pub-id-type="other">2-s2.0-84942506403</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>J.</given-names></name>
<name><surname>Fan</surname><given-names>Y. Q.</given-names></name>
<name><surname>Zhang</surname><given-names>H. L.</given-names></name>
<etal/>
</person-group><article-title>Resveratrol suppresses doxorubicin-induced cardiotoxicity by disrupting E2F1 mediated autophagy inhibition and apoptosis promotion</article-title><source>
<italic>Biochemical Pharmacology</italic>
</source><year>2018</year><volume>150</volume><fpage>202</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2018.02.025</pub-id><pub-id pub-id-type="other">2-s2.0-85042396958</pub-id><pub-id pub-id-type="pmid">29475062</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willis</surname><given-names>M. S.</given-names></name>
<name><surname>Parry</surname><given-names>T. L.</given-names></name>
<name><surname>Brown</surname><given-names>D. I.</given-names></name>
<etal/>
</person-group><article-title>Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1</article-title><source>
<italic>Circulation: Heart Failure</italic>
</source><year>2019</year><volume>12</volume><pub-id pub-id-type="publisher-id">e005234</pub-id><pub-id pub-id-type="doi">10.1161/circheartfailure.118.005234</pub-id><pub-id pub-id-type="other">2-s2.0-85062955400</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>W.</given-names></name>
<name><surname>Song</surname><given-names>Z. P.</given-names></name>
<name><surname>Chen</surname><given-names>Y. G.</given-names></name>
<name><surname>Zhang</surname><given-names>D. D.</given-names></name>
<name><surname>Wang</surname><given-names>C. Q.</given-names></name>
</person-group><article-title>Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity</article-title><source>
<italic>International Immunopharmacology</italic>
</source><year>2016</year><volume>32</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2016.01.002</pub-id><pub-id pub-id-type="other">2-s2.0-84954109353</pub-id><pub-id pub-id-type="pmid">26774212</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russo</surname><given-names>M.</given-names></name>
<name><surname>Guida</surname><given-names>F.</given-names></name>
<name><surname>Paparo</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>The novel butyrate derivative phenylalanine&#x02010;butyramide protects from doxorubicin&#x02010;induced cardiotoxicity</article-title><source>
<italic>European Journal of Heart Failure</italic>
</source><year>2019</year><volume>21</volume><issue>4</issue><fpage>519</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1439</pub-id><pub-id pub-id-type="other">2-s2.0-85062701953</pub-id><pub-id pub-id-type="pmid">30843309</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swenson</surname><given-names>C. E.</given-names></name>
<name><surname>Haemmerich</surname><given-names>D.</given-names></name>
<name><surname>Maul</surname><given-names>D. H.</given-names></name>
<name><surname>Knox</surname><given-names>B.</given-names></name>
<name><surname>Ehrhart</surname><given-names>N.</given-names></name>
<name><surname>Reed</surname><given-names>R. A.</given-names></name>
</person-group><article-title>Increased duration of heating boosts local drug deposition during radiofrequency ablation in combination with thermally sensitive liposomes (ThermoDox) in a porcine model</article-title><source>
<italic>PLoS One</italic>
</source><year>2015</year><volume>10</volume><issue>10</issue><pub-id pub-id-type="publisher-id">e0139752</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0139752</pub-id><pub-id pub-id-type="other">2-s2.0-84947260810</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>X. B.</given-names></name>
<name><surname>Zhang</surname><given-names>J. M.</given-names></name>
<name><surname>Xie</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>pH-sensitive micelles based on acid-labile pluronic F68-curcumin conjugates for improved tumor intracellular drug delivery</article-title><source>
<italic>International Journal of Pharmaceutics</italic>
</source><year>2016</year><volume>502</volume><issue>1-2</issue><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.01.029</pub-id><pub-id pub-id-type="other">2-s2.0-84959017497</pub-id><pub-id pub-id-type="pmid">26784981</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bendale</surname><given-names>Y.</given-names></name>
<name><surname>Bendale</surname><given-names>V.</given-names></name>
<name><surname>Paul</surname><given-names>S.</given-names></name>
</person-group><article-title>Evaluation of cytotoxic activity of platinum nanoparticles against normal and cancer cells and its anticancer potential through induction of apoptosis</article-title><source>
<italic>Integrative Medicine Research</italic>
</source><year>2017</year><volume>6</volume><issue>2</issue><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.imr.2017.01.006</pub-id><pub-id pub-id-type="pmid">28664137</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Iwahata</surname><given-names>H.</given-names></name>
<name><surname>Rogers</surname><given-names>H. B.</given-names></name>
<name><surname>Woodruff</surname><given-names>T. K.</given-names></name>
</person-group><article-title>Doxorubicin has dose-dependent toxicity on mouse ovarian follicle development, hormone secretion, and oocyte maturation</article-title><source>
<italic>Toxicological Sciences</italic>
</source><year>2017</year><volume>157</volume><issue>2</issue><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfx047</pub-id><pub-id pub-id-type="other">2-s2.0-85021695526</pub-id><pub-id pub-id-type="pmid">28329872</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.-Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.-J.</given-names></name>
<name><surname>Kim</surname><given-names>B.-J.</given-names></name>
<etal/>
</person-group><article-title>Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+increase are reciprocally modulated in rat cardiomyocytes</article-title><source>
<italic>Experimental and Molecular Medicine</italic>
</source><year>2006</year><volume>38</volume><issue>5</issue><fpage>535</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/emm.2006.63</pub-id><pub-id pub-id-type="other">2-s2.0-33750694593</pub-id><pub-id pub-id-type="pmid">17079870</pub-id></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotamraju</surname><given-names>S.</given-names></name>
<name><surname>Kalivendi</surname><given-names>S. V.</given-names></name>
<name><surname>Konorev</surname><given-names>E.</given-names></name>
<name><surname>Chitambar</surname><given-names>C. R.</given-names></name>
<name><surname>Joseph</surname><given-names>J.</given-names></name>
<name><surname>Kalyanaraman</surname><given-names>B.</given-names></name>
</person-group><article-title>Oxidant-induced iron signaling in doxorubicin-mediated apoptosis</article-title><source>
<italic>Quinones and Quinone Enzymes, Part A</italic>
</source><year>2004</year><volume>378</volume><fpage>362</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(04)78026-X</pub-id><pub-id pub-id-type="other">2-s2.0-3042828610</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwok</surname><given-names>J. C.</given-names></name>
<name><surname>Richardson</surname><given-names>D. R.</given-names></name>
</person-group><article-title>Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway</article-title><source>
<italic>Molecular Pharmacology</italic>
</source><year>2003</year><volume>63</volume><issue>4</issue><fpage>849</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1124/mol.63.4.849</pub-id><pub-id pub-id-type="other">2-s2.0-0037379680</pub-id><pub-id pub-id-type="pmid">12644586</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mukhopadhyay</surname><given-names>P.</given-names></name>
<name><surname>Rajesh</surname><given-names>M.</given-names></name>
<name><surname>B&#x000e1;tkai</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro</article-title><source>
<italic>American Journal of Physiology&#x02014;Heart and Circulatory Physiology</italic>
</source><year>2009</year><volume>296</volume><issue>5</issue><pub-id pub-id-type="doi">10.1152/ajpheart.00795.2008</pub-id><pub-id pub-id-type="other">2-s2.0-66149110905</pub-id></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>H. S.</given-names></name>
<name><surname>Besla</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Paradoxical suppression of atherosclerosis in the absence of microRNA-146a</article-title><source>
<italic>Circulation Research</italic>
</source><year>2017</year><volume>121</volume><issue>4</issue><fpage>354</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1161/circresaha.116.310529</pub-id><pub-id pub-id-type="other">2-s2.0-85026812154</pub-id><pub-id pub-id-type="pmid">28637783</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>del Monte</surname><given-names>A.</given-names></name>
<name><surname>Arroyo</surname><given-names>A. B.</given-names></name>
<name><surname>Andr&#x000e9;s-Manzano</surname><given-names>M. J.</given-names></name>
<etal/>
</person-group><article-title>miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis</article-title><source>
<italic>PLoS One</italic>
</source><year>2018</year><volume>13</volume><issue>6</issue><pub-id pub-id-type="publisher-id">e0198932</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0198932</pub-id><pub-id pub-id-type="other">2-s2.0-85059293427</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Tian</surname><given-names>S. S.</given-names></name>
<name><surname>Hang</surname><given-names>P. Z.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<name><surname>Du</surname><given-names>Z. M.</given-names></name>
</person-group><article-title>Combination of microRNA-21 and microRNA-146a attenuates cardiac dysfunction and apoptosis during acute myocardial infarction in mice</article-title><source>
<italic>Molecular Therapy-Nucleic Acids</italic>
</source><year>2016</year><volume>5</volume><pub-id pub-id-type="doi">10.1038/mtna.2016.12</pub-id><pub-id pub-id-type="other">2-s2.0-85015666348</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Ha</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury</article-title><source>
<italic>Cardiovascular Research</italic>
</source><year>2013</year><volume>97</volume><issue>3</issue><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvs356</pub-id><pub-id pub-id-type="other">2-s2.0-84874242882</pub-id><pub-id pub-id-type="pmid">23208587</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Gordon</surname><given-names>A. D.</given-names></name>
<name><surname>Chakrabarti</surname><given-names>S.</given-names></name>
</person-group><article-title>miR-146a mediates inflammatory changes and fibrosis in the heart in diabetes</article-title><source>
<italic>Journal of Molecular and Cellular Cardiology</italic>
</source><year>2017</year><volume>105</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2017.03.002</pub-id><pub-id pub-id-type="other">2-s2.0-85014885950</pub-id><pub-id pub-id-type="pmid">28279663</pub-id></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Huang</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Troxerutin attenuates myocardial cell apoptosis following myocardial ischemia&#x02010;reperfusion injury through inhibition of miR&#x02010;146a&#x02010;5p expression</article-title><source>
<italic>Journal of Cellular Physiology</italic>
</source><year>2019</year><volume>234</volume><issue>6</issue><pub-id pub-id-type="doi">10.1002/jcp.27607</pub-id><pub-id pub-id-type="other">2-s2.0-85056262638</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>X. P.</given-names></name>
<name><surname>Wan</surname><given-names>L. L.</given-names></name>
<name><surname>Yang</surname><given-names>Q. J.</given-names></name>
<name><surname>Huo</surname><given-names>Y.</given-names></name>
<name><surname>Han</surname><given-names>Y. L.</given-names></name>
<name><surname>Guo</surname><given-names>C.</given-names></name>
</person-group><article-title>Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart</article-title><source>
<italic>Archives of Pharmacal Research</italic>
</source><year>2017</year><volume>40</volume><issue>7</issue><fpage>875</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1007/s12272-017-0907-0</pub-id><pub-id pub-id-type="other">2-s2.0-85015627007</pub-id><pub-id pub-id-type="pmid">28315259</pub-id></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohlig</surname><given-names>J.</given-names></name>
<name><surname>Henninger</surname><given-names>C.</given-names></name>
<name><surname>Zander</surname><given-names>S.</given-names></name>
<name><surname>Merx</surname><given-names>M.</given-names></name>
<name><surname>Kelm</surname><given-names>M.</given-names></name>
<name><surname>Fritz</surname><given-names>G.</given-names></name>
</person-group><article-title>Rac1-mediated cardiac damage causes diastolic dysfunction in a mouse model of subacute doxorubicin-induced cardiotoxicity</article-title><source>
<italic>Archives of Toxicology</italic>
</source><year>2018</year><volume>92</volume><issue>1</issue><fpage>441</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1007/s00204-017-2017-7</pub-id><pub-id pub-id-type="other">2-s2.0-85023738868</pub-id><pub-id pub-id-type="pmid">28710503</pub-id></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Bracken</surname><given-names>C. P.</given-names></name>
<name><surname>Pillman</surname><given-names>K. A.</given-names></name>
<etal/>
</person-group><article-title>p53 represses the oncogenic sno-MiR-28 derived from a SnoRNA</article-title><source>
<italic>PLoS One</italic>
</source><year>2015</year><volume>10</volume><issue>6</issue><pub-id pub-id-type="publisher-id">e0129190</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0129190</pub-id><pub-id pub-id-type="other">2-s2.0-84936804323</pub-id></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herrera</surname><given-names>F. J.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>T.</given-names></name>
<name><surname>Roelink</surname><given-names>H.</given-names></name>
<name><surname>Tjian</surname><given-names>R.</given-names></name>
</person-group><article-title>Core promoter factor TAF9B regulates neuronal gene expression</article-title><source>
<italic>Elife</italic>
</source><year>2014</year><volume>3</volume><pub-id pub-id-type="publisher-id">e02559</pub-id><pub-id pub-id-type="doi">10.7554/elife.02559</pub-id></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simabuco</surname><given-names>F. M.</given-names></name>
<name><surname>Morale</surname><given-names>M. G.</given-names></name>
<name><surname>Pavan</surname><given-names>I. C. B.</given-names></name>
<name><surname>Morelli</surname><given-names>A. P.</given-names></name>
<name><surname>Silva</surname><given-names>F. R.</given-names></name>
<name><surname>Tamura</surname><given-names>R. E.</given-names></name>
</person-group><article-title>p53 and metabolism: from mechanism to therapeutics</article-title><source>
<italic>Oncotarget</italic>
</source><year>2018</year><volume>9</volume><issue>34</issue><pub-id pub-id-type="doi">10.18632/oncotarget.25267</pub-id><pub-id pub-id-type="other">2-s2.0-85046706242</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frontini</surname><given-names>M.</given-names></name>
<name><surname>Soutoglou</surname><given-names>E.</given-names></name>
<name><surname>Argentini</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>TAF9b (formerly TAF9L) is a bona fide TAF that has unique and overlapping roles with TAF9</article-title><source>
<italic>Molecular and Cellular Biology</italic>
</source><year>2005</year><volume>25</volume><issue>11</issue><pub-id pub-id-type="doi">10.1128/mcb.25.11.4638-4649.2005</pub-id><pub-id pub-id-type="other">2-s2.0-18944404538</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>J.-A.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>J.-Y.</given-names></name>
<etal/>
</person-group><article-title>miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b/P53 pathway in doxorubicin-induced cardiotoxicity</article-title><source>
<italic>Cell Death &#x00026; Disease</italic>
</source><year>2019</year><volume>10</volume><issue>9</issue><pub-id pub-id-type="doi">10.1038/s41419-019-1901-x</pub-id><pub-id pub-id-type="other">2-s2.0-85072111500</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahn</surname><given-names>D.</given-names></name>
<name><surname>Cheng</surname><given-names>L.</given-names></name>
<name><surname>Moon</surname><given-names>C.</given-names></name>
<name><surname>Spurgeon</surname><given-names>H.</given-names></name>
<name><surname>Lakatta</surname><given-names>E. G.</given-names></name>
<name><surname>Talan</surname><given-names>M. I.</given-names></name>
</person-group><article-title>Induction of myocardial infarcts of a predictable size and location by branch pattern probability-assisted coronary ligation in C57BL/6 mice</article-title><source>
<italic>American Journal of Physiology - Heart and Circulatory Physiology</italic>
</source><year>2004</year><volume>286</volume><issue>3</issue><pub-id pub-id-type="doi">10.1152/ajpheart.00862.2003</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>C. S.</given-names></name>
<name><surname>Kim</surname><given-names>H. K.</given-names></name>
<name><surname>Mishchenko</surname><given-names>N. P.</given-names></name>
<etal/>
</person-group><article-title>The protective effects of echinochrome a structural analogs against oxidative stress and doxorubicin in AC16 cardiomyocytes</article-title><source>
<italic>Molecular &#x00026; Cellular Toxicology</italic>
</source><year>2019</year><volume>15</volume><issue>4</issue><pub-id pub-id-type="doi">10.1007/s13273-019-0044-6</pub-id><pub-id pub-id-type="other">2-s2.0-85073235226</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>A.</given-names></name>
<name><surname>Rohlfsen</surname><given-names>C.</given-names></name>
<name><surname>Leppo</surname><given-names>M. K.</given-names></name>
<etal/>
</person-group><article-title>Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity</article-title><source>
<italic>PLoS One</italic>
</source><year>2013</year><volume>8</volume><issue>10</issue><pub-id pub-id-type="publisher-id">e74675</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0074675</pub-id><pub-id pub-id-type="other">2-s2.0-84885084776</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Upadhyay</surname><given-names>K. K.</given-names></name>
<name><surname>Mishra</surname><given-names>A. K.</given-names></name>
<name><surname>Chuttani</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>The in vivo behavior and antitumor activity of doxorubicin-loaded poly(<italic>&#x003b3;</italic>-benzyl l-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice</article-title><source>
<italic>Nanomedicine: Nanotechnology, Biology and Medicine</italic>
</source><year>2012</year><volume>8</volume><issue>1</issue><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2011.05.008</pub-id><pub-id pub-id-type="other">2-s2.0-84855312140</pub-id><pub-id pub-id-type="pmid">21703363</pub-id></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohan</surname><given-names>P.</given-names></name>
<name><surname>Rapoport</surname><given-names>N.</given-names></name>
</person-group><article-title>Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking</article-title><source>
<italic>Molecular Pharmaceutics</italic>
</source><year>2010</year><volume>7</volume><issue>6</issue><pub-id pub-id-type="doi">10.1021/mp100269f</pub-id><pub-id pub-id-type="other">2-s2.0-78649934894</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Altieri</surname><given-names>P.</given-names></name>
<name><surname>Barisione</surname><given-names>C.</given-names></name>
<name><surname>Lazzarini</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Testosterone antagonizes doxorubicin&#x02010;induced senescence of cardiomyocytes</article-title><source>
<italic>Journal of American Heart Association</italic>
</source><year>2016</year><volume>5</volume><issue>1</issue><pub-id pub-id-type="publisher-id">e002383</pub-id><pub-id pub-id-type="doi">10.1161/jaha.115.002383</pub-id><pub-id pub-id-type="other">2-s2.0-84997831746</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malla</surname><given-names>S.</given-names></name>
<name><surname>Niraula</surname><given-names>N. P.</given-names></name>
<name><surname>Liou</surname><given-names>K.</given-names></name>
<name><surname>Sohng</surname><given-names>J. K.</given-names></name>
</person-group><article-title>Self-resistance mechanism in Streptomyces peucetius: overexpression of drrA, drrB and drrC for doxorubicin enhancement</article-title><source>
<italic>Microbiological Research</italic>
</source><year>2010</year><volume>165</volume><issue>4</issue><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2009.04.002</pub-id><pub-id pub-id-type="other">2-s2.0-77954460353</pub-id><pub-id pub-id-type="pmid">19651502</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koleini</surname><given-names>N.</given-names></name>
<name><surname>Nickel</surname><given-names>B. E.</given-names></name>
<name><surname>Edel</surname><given-names>A. L.</given-names></name>
<name><surname>Fandrich</surname><given-names>R. R.</given-names></name>
<name><surname>Ravandi</surname><given-names>A.</given-names></name>
<name><surname>Kardami</surname><given-names>E.</given-names></name>
</person-group><article-title>Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway</article-title><source>
<italic>Cell and Tissue Research</italic>
</source><year>2018</year><volume>374</volume><issue>3</issue><fpage>607</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1007/s00441-018-2905-z</pub-id><pub-id pub-id-type="other">2-s2.0-85053239945</pub-id><pub-id pub-id-type="pmid">30159756</pub-id></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niraula</surname><given-names>N. P.</given-names></name>
<name><surname>Kim</surname><given-names>S. H.</given-names></name>
<name><surname>Sohng</surname><given-names>J. K.</given-names></name>
<name><surname>Kim</surname><given-names>E. S.</given-names></name>
</person-group><article-title>Biotechnological doxorubicin production: pathway and regulation engineering of strains for enhanced production</article-title><source>
<italic>Applied Microbiology and Biotechnology</italic>
</source><year>2010</year><volume>87</volume><issue>4</issue><pub-id pub-id-type="doi">10.1007/s00253-010-2675-3</pub-id><pub-id pub-id-type="other">2-s2.0-77955551494</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ichikawa</surname><given-names>Y.</given-names></name>
<name><surname>Ghanefar</surname><given-names>M.</given-names></name>
<name><surname>Bayeva</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation</article-title><source>
<italic>Journal of Clinical Investigation</italic>
</source><year>2014</year><volume>124</volume><issue>2</issue><fpage>617</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1172/jci72931</pub-id><pub-id pub-id-type="other">2-s2.0-84893845965</pub-id><pub-id pub-id-type="pmid">24382354</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghigo</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Hirsch</surname><given-names>E.</given-names></name>
</person-group><article-title>New signal transduction paradigms in anthracycline-induced cardiotoxicity</article-title><source>
<italic>Biochimica et Biophysica Acta (BBA)-Molecular Cell Research</italic>
</source><year>2016</year><volume>1863</volume><issue>7</issue><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.01.021</pub-id><pub-id pub-id-type="other">2-s2.0-84957921445</pub-id></element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rauscher</surname><given-names>H.</given-names></name>
<name><surname>Sokull-Kl&#x000fc;ttgen</surname><given-names>B.</given-names></name>
<name><surname>Stamm</surname><given-names>H.</given-names></name>
</person-group><article-title>The European commission&#x02019;s recommendation on the definition of nanomaterial makes an impact</article-title><source>
<italic>Nanotoxicology</italic>
</source><year>2012</year><volume>7</volume><pub-id pub-id-type="doi">10.3109/17435390.2012.724724</pub-id><pub-id pub-id-type="other">2-s2.0-84885116495</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pugazhendhi</surname><given-names>A.</given-names></name>
<name><surname>Edison</surname><given-names>T. N. J. I.</given-names></name>
<name><surname>Velmurugan</surname><given-names>B. K.</given-names></name>
<name><surname>Jacob</surname><given-names>J. A.</given-names></name>
<name><surname>Karuppusamy</surname><given-names>I.</given-names></name>
</person-group><article-title>Toxicity of Doxorubicin (Dox) to different experimental organ systems</article-title><source>
<italic>Life Sciences</italic>
</source><year>2018</year><volume>200</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2018.03.023</pub-id><pub-id pub-id-type="other">2-s2.0-85043585462</pub-id><pub-id pub-id-type="pmid">29534993</pub-id></element-citation></ref><ref id="B44" content-type="article"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thorn</surname><given-names>C. F.</given-names></name>
<name><surname>Oshiro</surname><given-names>C.</given-names></name>
<name><surname>Marsh</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Doxorubicin pathways</article-title><source>
<italic>Pharmacogenetics and Genomics</italic>
</source><year>2011</year><volume>21</volume><issue>7</issue><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1097/fpc.0b013e32833ffb56</pub-id><pub-id pub-id-type="other">2-s2.0-79959805353</pub-id><pub-id pub-id-type="pmid">21048526</pub-id></element-citation></ref><ref id="B45" content-type="article"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>La Ferla</surname><given-names>B.</given-names></name>
<name><surname>Airoldi</surname><given-names>C.</given-names></name>
<name><surname>Zona</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Natural glycoconjugates with antitumor activity</article-title><source>
<italic>Natural Product Reports</italic>
</source><year>2011</year><volume>28</volume><issue>3</issue><fpage>630</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1039/c0np00055h</pub-id><pub-id pub-id-type="other">2-s2.0-79952033077</pub-id><pub-id pub-id-type="pmid">21120227</pub-id></element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>J.</given-names></name>
<name><surname>Nakamura</surname><given-names>H.</given-names></name>
<name><surname>Maeda</surname><given-names>H.</given-names></name>
</person-group><article-title>The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect</article-title><source>
<italic>Advanced Drug Delivery Reviews</italic>
</source><year>2011</year><volume>63</volume><issue>3</issue><fpage>136</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2010.04.009</pub-id><pub-id pub-id-type="other">2-s2.0-79953054576</pub-id><pub-id pub-id-type="pmid">20441782</pub-id></element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vinken</surname><given-names>M.</given-names></name>
</person-group><article-title>The adverse outcome pathway concept: a pragmatic tool in toxicology</article-title><source>
<italic>Toxicology</italic>
</source><year>2013</year><volume>312</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2013.08.011</pub-id><pub-id pub-id-type="other">2-s2.0-84884179017</pub-id><pub-id pub-id-type="pmid">23978457</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Qi</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Dong</surname><given-names>L.</given-names></name>
</person-group><article-title>Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage</article-title><source>
<italic>Cancer Research</italic>
</source><year>2016</year><volume>76</volume><issue>22</issue><fpage>6631</fpage><lpage>6642</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-15-3034</pub-id><pub-id pub-id-type="other">2-s2.0-84995511357</pub-id><pub-id pub-id-type="pmid">27680684</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oleaga</surname><given-names>C.</given-names></name>
<name><surname>Bernabini</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>A. S.</given-names></name>
<etal/>
</person-group><article-title>Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs</article-title><source>
<italic>Scientific Reports</italic>
</source><year>2016</year><volume>6</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/srep20030</pub-id><pub-id pub-id-type="other">2-s2.0-84957586265</pub-id></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1</article-title><source>
<italic>Pharmacological Research</italic>
</source><year>2019</year><volume>146</volume><pub-id pub-id-type="publisher-id">104276</pub-id><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104276</pub-id><pub-id pub-id-type="other">2-s2.0-85066049672</pub-id></element-citation></ref><ref id="B51" content-type="article"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Qi</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2</article-title><source>
<italic>Redox Biology</italic>
</source><year>2018</year><volume>15</volume><fpage>284</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2017.12.013</pub-id><pub-id pub-id-type="other">2-s2.0-85039838234</pub-id><pub-id pub-id-type="pmid">29304479</pub-id></element-citation></ref><ref id="B52" content-type="article"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Duan</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Upregulation of let-7f-2-3p by long noncoding RNA NEAT1 inhibits XPO1-mediated HAX-1 nuclear export in both in vitro and in vivo rodent models of doxorubicin-induced cardiotoxicity</article-title><source>
<italic>Archives of Toxicology</italic>
</source><year>2019</year><volume>93</volume><issue>11</issue><pub-id pub-id-type="doi">10.1007/s00204-019-02586-4</pub-id><pub-id pub-id-type="other">2-s2.0-85073996564</pub-id></element-citation></ref><ref id="B53" content-type="article"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanouskov&#x000e1;</surname><given-names>B.</given-names></name>
<name><surname>Sk&#x000e1;la</surname><given-names>M.</given-names></name>
<name><surname>Brynychov&#x000e1;</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Imatinib-induced changes in the expression profile of microRNA in the plasma and heart of mice-A comparison with doxorubicin</article-title><source>
<italic>Biomedicine &#x00026; Pharmacotherapy</italic>
</source><year>2019</year><volume>115</volume><pub-id pub-id-type="publisher-id">108883</pub-id><pub-id pub-id-type="doi">10.1016/j.biopha.2019.108883</pub-id><pub-id pub-id-type="other">2-s2.0-85064453278</pub-id></element-citation></ref><ref id="B54" content-type="article"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pakravan</surname><given-names>G.</given-names></name>
<name><surname>Foroughmand</surname><given-names>A. M.</given-names></name>
<name><surname>Peymani</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Downregulation of miR-130a, antagonized doxorubicin-induced cardiotoxicity via increasing the PPAR<italic>&#x003b3;</italic> expression in mESCs-derived cardiac cells</article-title><source>
<italic>Cell Death &#x00026; Disease</italic>
</source><year>2018</year><volume>9</volume><issue>7</issue><fpage>p. 758</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-0797-1</pub-id><pub-id pub-id-type="other">2-s2.0-85049730641</pub-id></element-citation></ref><ref id="B55" content-type="article"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beaumier</surname><given-names>A.</given-names></name>
<name><surname>Robinson</surname><given-names>S. R.</given-names></name>
<name><surname>Robinson</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin&#x02010;induced cardiotoxicity</article-title><source>
<italic>Journal of Veterinary Internal Medicine</italic>
</source><year>2020</year><volume>34</volume><issue>3</issue><pub-id pub-id-type="doi">10.1111/jvim.15762</pub-id></element-citation></ref><ref id="B56" content-type="article"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leger</surname><given-names>K. J.</given-names></name>
<name><surname>Leonard</surname><given-names>D.</given-names></name>
<name><surname>Nielson</surname><given-names>D.</given-names></name>
<name><surname>de Lemos</surname><given-names>J. A.</given-names></name>
<name><surname>Mammen</surname><given-names>P. P. A.</given-names></name>
<name><surname>Winick</surname><given-names>N. J.</given-names></name>
</person-group><article-title>Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy</article-title><source>
<italic>Journal of American Heart Association</italic>
</source><year>2017</year><volume>6</volume><issue>4</issue><pub-id pub-id-type="publisher-id">e004653</pub-id><pub-id pub-id-type="doi">10.1161/jaha.116.004653</pub-id><pub-id pub-id-type="other">2-s2.0-85031851236</pub-id></element-citation></ref><ref id="B57" content-type="article"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wan</surname><given-names>G. X.</given-names></name>
<name><surname>Cheng</surname><given-names>L.</given-names></name>
<name><surname>Qin</surname><given-names>H. L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y. Z.</given-names></name>
<name><surname>Wang</surname><given-names>L. Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y. G.</given-names></name>
</person-group><article-title>MiR-15b-5p is involved in doxorubicin-induced cardiotoxicity via inhibiting Bmpr1a signal in H9c2 cardiomyocyte</article-title><source>
<italic>Cardiovascular Toxicology</italic>
</source><year>2019</year><volume>19</volume><issue>3</issue><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1007/s12012-018-9495-6</pub-id><pub-id pub-id-type="other">2-s2.0-85058096599</pub-id><pub-id pub-id-type="pmid">30535663</pub-id></element-citation></ref><ref id="B58" content-type="article"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bravo-San Pedro</surname><given-names>J. M.</given-names></name>
<name><surname>Kroemer</surname><given-names>G.</given-names></name>
<name><surname>Galluzzi</surname><given-names>L.</given-names></name>
</person-group><article-title>Autophagy and mitophagy in cardiovascular disease</article-title><source>
<italic>Circulation Research</italic>
</source><year>2017</year><volume>120</volume><issue>11</issue><pub-id pub-id-type="doi">10.1161/circresaha.117.311082</pub-id><pub-id pub-id-type="other">2-s2.0-85019766584</pub-id></element-citation></ref><ref id="B59" content-type="article"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takemura</surname><given-names>G.</given-names></name>
<name><surname>Kanamori</surname><given-names>H.</given-names></name>
<name><surname>Okada</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Anti-apoptosis in nonmyocytes and pro-autophagy in cardiomyocytes: two strategies against postinfarction heart failure through regulation of cell death/degeneration</article-title><source>
<italic>Heart Failure Reviews</italic>
</source><year>2018</year><volume>23</volume><issue>5</issue><fpage>759</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1007/s10741-018-9708-x</pub-id><pub-id pub-id-type="other">2-s2.0-85046666855</pub-id><pub-id pub-id-type="pmid">29737434</pub-id></element-citation></ref><ref id="B60" content-type="article"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Protective effect of berberine on doxorubicin-induced acute hepatorenal toxicity in rats</article-title><source>
<italic>Molecular Medicine Reports</italic>
</source><year>2016</year><volume>13</volume><issue>5</issue><pub-id pub-id-type="doi">10.3892/mmr.2016.5017</pub-id><pub-id pub-id-type="other">2-s2.0-84964744617</pub-id></element-citation></ref><ref id="B61" content-type="article"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
</person-group><article-title>Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes</article-title><source>
<italic>Scientific Reports</italic>
</source><year>2017</year><volume>7</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/srep44735</pub-id><pub-id pub-id-type="other">2-s2.0-85015696764</pub-id></element-citation></ref><ref id="B62" content-type="article"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S. H.</given-names></name>
<name><surname>Kim</surname><given-names>K. J.</given-names></name>
<name><surname>Kim</surname><given-names>J. H.</given-names></name>
<etal/>
</person-group><article-title>Comparision of doxorubicin-induced cardiotoxicity in the ICR mice of different sources</article-title><source>
<italic>Laboratory Animal Research</italic>
</source><year>2017</year><volume>33</volume><issue>2</issue><pub-id pub-id-type="doi">10.5625/lar.2017.33.2.165</pub-id></element-citation></ref><ref id="B63" content-type="article"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Protective effects of tannic acid on acute doxorubicin-induced cardiotoxicity: involvement of suppression in oxidative stress, inflammation, and apoptosis</article-title><source>
<italic>Biomedicine &#x00026; Pharmacotherapy</italic>
</source><year>2017</year><volume>93</volume><pub-id pub-id-type="doi">10.1016/j.biopha.2017.07.051</pub-id><pub-id pub-id-type="other">2-s2.0-85025081601</pub-id></element-citation></ref><ref id="B64" content-type="article"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Hou</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>miR-199-sponge transgenic mice develop physiological cardiac hypertrophy</article-title><source>
<italic>Cardiovascular Research</italic>
</source><year>2016</year><volume>110</volume><issue>2</issue><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw052</pub-id><pub-id pub-id-type="other">2-s2.0-84966615441</pub-id><pub-id pub-id-type="pmid">26976621</pub-id></element-citation></ref><ref id="B65" content-type="article"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baumgarten</surname><given-names>A.</given-names></name>
<name><surname>Bang</surname><given-names>C.</given-names></name>
<name><surname>Tschirner</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy</article-title><source>
<italic>International Journal of Cardiology</italic>
</source><year>2013</year><volume>168</volume><issue>2</issue><pub-id pub-id-type="doi">10.1016/j.ijcard.2012.12.094</pub-id><pub-id pub-id-type="other">2-s2.0-84885330287</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Cardiomyocytes (AC16 cells) was injured by DOX. (a) The cell proliferation rate in the DOX induction group was distinctly lower than that in the control group. (b) The levels of TNF-<italic>&#x003b1;</italic>, IL-1<italic>&#x003b2;</italic>, and IL-6 in the DOX induction group were obviously higher. (c) The LDH and MDA in the DOX induction group was higher than that in the control group, while SOD in the DOX induction group decreased relatively to the control group. (d) Cell apoptosis detection by flow cytometry. (e) Detection of apoptosis cells by TUNEL staining. (f-g) Apoptosis-related protein expression detection by qPCR. (h) Beclin-1 and LC3B expression detection by western blotting. <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01, and <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="ECAM2022-4364779.001" position="float"/></fig><fig position="float" id="fig2"><label>Figure 2</label><caption><p>DOX promotes the expression of miR-199. (a) Detection of miR-199 in DOX-mediated cell model. (b) Detection of miR-199 in DOX-mediated mice model. (c) The myocardial tissue injury was observed by HE staining. <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05 and <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="ECAM2022-4364779.002" position="float"/></fig><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Overexpression of miR-199 promotes the DOX-mediated cardiotoxicity. (a) Detection of miR-199 expression level in AC16 cells model after different treatment. (b) Detection of TNF-<italic>&#x003b1;</italic>, IL-1<italic>&#x003b2;</italic>, and IL-6 after different treatment. (c) Detection of LDH, SOD, and MDA by ELISA method. (d) Cell apoptosis test by TUNEL staining. (e) Cell apoptosis test by flow cytometry. (f) &#x00026; (g) Detection of mRNA levels of Bax and Bcl-2 by RT-qPCR. (h) Beclin-1 and LC3B detection by western blotting. <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01, and <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001. Magnification: 200x.</p></caption><graphic xlink:href="ECAM2022-4364779.003" position="float"/></fig><fig position="float" id="fig4"><label>Figure 4</label><caption><p>TAF9b binds to miR-199 as a target gene. (a) The schematic diagram of the combination of miR-199 and TAF9b. (b) Detection of TAF9b in DOX-mediated AC16 cell model. (c) Detection of TAF9b expression level in DOX-mediated mice model. (d) Detection of TAF9b expression level after different treatment by RT-qPCR. (e) Detection of TAF9b expression level after different treatment by RT-qPCR. <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01 and <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="ECAM2022-4364779.004" position="float"/></fig><fig position="float" id="fig5"><label>Figure 5</label><caption><p>Knockdown of TAF9b reverses the cardioprotective influence on miR-199 inhibitor. (a) Detection of TAF9b expression level. (b) Detection of TAF9b expression level in AC16 cells model after different treatment. (c) Cell viability test by CCK-8 method. (d) Detection of TNF-<italic>&#x003b1;</italic>, IL-1<italic>&#x003b2;</italic>, and IL-6 after different treatment. (e) Detection of the content of LDH, SOD, and MDA in DOX-mediated cell model by ELISA method. (f) Bax and Bcl-2 test by RT-qPCR. <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01, and <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="ECAM2022-4364779.005" position="float"/></fig><fig position="float" id="fig6"><label>Figure 6</label><caption><p>Overexpression of TAF9b reverses injury mediated by miR-199. (a) Transfection efficiency of TAF9b overexpressing plasmid. (b) Detection of AC16 cell apoptosis by flow cytometry. (c) AC16 cell apoptosis test by TUNEL staining. (d, e) Detection of mRNA level of Bax and Bcl-2 by RT-qPCR. (f) Beclin-1 and LC3B expression detection by western blotting. <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01, and <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="ECAM2022-4364779.006" position="float"/></fig></floats-group></article>